Emergent (EBS) Begins Dosing in Study on Influenza Vaccine Posted byZacks Equity Research December 17, 2021 Leave a comment on Emergent (EBS) Begins Dosing in Study on Influenza Vaccine Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company’s investigational universal influenza vaccine candidate.